journal
Journals Signal Transduction and Target...

Signal Transduction and Targeted Therapy

https://read.qxmd.com/read/38653754/sry-box-transcription-factor-9-triggers-yap-nuclear-entry-via-direct-interaction-in-tumors
#21
JOURNAL ARTICLE
Hui Qian, Chen-Hong Ding, Fang Liu, Shi-Jie Chen, Chen-Kai Huang, Meng-Chao Xiao, Xia-Lu Hong, Ming-Chen Wang, Fang-Zhi Yan, Kai Ding, Ya-Lu Cui, Bai-Nan Zheng, Jin Ding, Cheng Luo, Xin Zhang, Wei-Fen Xie
The translocation of YAP from the cytoplasm to the nucleus is critical for its activation and plays a key role in tumor progression. However, the precise molecular mechanisms governing the nuclear import of YAP are not fully understood. In this study, we have uncovered a crucial role of SOX9 in the activation of YAP. SOX9 promotes the nuclear translocation of YAP by direct interaction. Importantly, we have identified that the binding between Asp-125 of SOX9 and Arg-124 of YAP is essential for SOX9-YAP interaction and subsequent nuclear entry of YAP...
April 24, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38654010/fgf7-enhances-the-expression-of-ace2-in-human-islet-organoids-aggravating-sars-cov-2-infection
#22
JOURNAL ARTICLE
Hao Meng, Zhiying Liao, Yanting Ji, Dong Wang, Yang Han, Chaolin Huang, Xujuan Hu, Jingyi Chen, Hengrui Zhang, Zonghong Li, Changliang Wang, Hui Sun, Jiaqi Sun, Lihua Chen, Jiaxiang Yin, Jincun Zhao, Tao Xu, Huisheng Liu
The angiotensin-converting enzyme 2 (ACE2) is a primary cell surface viral binding receptor for SARS-CoV-2, so finding new regulatory molecules to modulate ACE2 expression levels is a promising strategy against COVID-19. In the current study, we utilized islet organoids derived from human embryonic stem cells (hESCs), animal models and COVID-19 patients to discover that fibroblast growth factor 7 (FGF7) enhances ACE2 expression within the islets, facilitating SARS-CoV-2 infection and resulting in impaired insulin secretion...
April 23, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38653983/efficacy-and-safety-of-human-umbilical-cord-derived-mesenchymal-stem-cells-in-the-treatment-of-refractory-immune-thrombocytopenia-a-prospective-single-arm-phase-i-trial
#23
JOURNAL ARTICLE
Yunfei Chen, Yanmei Xu, Ying Chi, Ting Sun, Yuchen Gao, Xueqing Dou, Zhibo Han, Feng Xue, Huiyuan Li, Wei Liu, Xiaofan Liu, Huan Dong, Rongfeng Fu, Mankai Ju, Xinyue Dai, Wentian Wang, Yueshen Ma, Zhen Song, Jundong Gu, Wei Gong, Renchi Yang, Lei Zhang
Patients with refractory immune thrombocytopenia (ITP) frequently encounter substantial bleeding risks and demonstrate limited responsiveness to existing therapies. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) present a promising alternative, capitalizing on their low immunogenicity and potent immunomodulatory effects for treating diverse autoimmune disorders. This prospective phase I trial enrolled eighteen eligible patients to explore the safety and efficacy of UC-MSCs in treating refractory ITP...
April 23, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38644381/pbx-knotted-1-homeobox-2-pknox2-is-a-novel-regulator-of-myocardial-fibrosis
#24
JOURNAL ARTICLE
Liang Chen, Haotong Li, Xiaorui Liu, Ningning Zhang, Kui Wang, Anteng Shi, Hang Gao, Deniz Akdis, Ardan M Saguner, Xinjie Xu, Elena Osto, Willem Van de Veen, Guangyu Li, Antoni Bayés-Genís, Firat Duru, Jiangping Song, Xiangjie Li, Shengshou Hu
Much effort has been made to uncover the cellular heterogeneities of human hearts by single-nucleus RNA sequencing. However, the cardiac transcriptional regulation networks have not been systematically described because of the limitations in detecting transcription factors. In this study, we optimized a pipeline for isolating nuclei and conducting single-nucleus RNA sequencing targeted to detect a higher number of cell signal genes and an optimal number of transcription factors. With this unbiased protocol, we characterized the cellular composition of healthy human hearts and investigated the transcriptional regulation networks involved in determining the cellular identities and functions of the main cardiac cell subtypes...
April 22, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38643203/a-novel-engineered-il-21-receptor-arms-t-cell-receptor-engineered-t-cells-tcr-t-cells-against-hepatocellular-carcinoma
#25
JOURNAL ARTICLE
Wei Zhu, Zhiming Zhang, Jinzhang Chen, Xiaolan Chen, Lei Huang, Xiaoyong Zhang, Xuan Huang, Na Ma, Weikang Xu, Xuan Yi, Xinyu Lu, Xin Fu, Siwei Li, Guoheng Mo, Yiyue Wang, Guosheng Yuan, Mengya Zang, Qi Li, Xiaotao Jiang, Yajing He, Sha Wu, Yukai He, Yongyin Li, Jinlin Hou
Strategies to improve T cell therapy efficacy in solid tumors such as hepatocellular carcinoma (HCC) are urgently needed. The common cytokine receptor γ chain (γc ) family cytokines such as IL-2, IL-7, IL-15 and IL-21 play fundamental roles in T cell development, differentiation and effector phases. This study aims to determine the combination effects of IL-21 in T cell therapy against HCC and investigate optimized strategies to utilize the effect of IL-21 signal in T cell therapy. The antitumor function of AFP-specific T cell receptor-engineered T cells (TCR-T) was augmented by exogenous IL-21 in vitro and in vivo...
April 20, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38637540/drug-repurposing-for-cancer-therapy
#26
REVIEW
Ying Xia, Ming Sun, Hai Huang, Wei-Lin Jin
Cancer, a complex and multifactorial disease, presents a significant challenge to global health. Despite significant advances in surgical, radiotherapeutic and immunological approaches, which have improved cancer treatment outcomes, drug therapy continues to serve as a key therapeutic strategy. However, the clinical efficacy of drug therapy is often constrained by drug resistance and severe toxic side effects, and thus there remains a critical need to develop novel cancer therapeutics. One promising strategy that has received widespread attention in recent years is drug repurposing: the identification of new applications for existing, clinically approved drugs...
April 19, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38637495/the-activity-and-immune-dynamics-of-pd-1-inhibition-on-high-risk-pulmonary-ground-glass-opacity-lesions-insights-from-a-single-arm-phase-ii-trial
#27
JOURNAL ARTICLE
Bo Cheng, Caichen Li, Jianfu Li, Longlong Gong, Peng Liang, Ying Chen, Shuting Zhan, Shan Xiong, Ran Zhong, Hengrui Liang, Yi Feng, Runchen Wang, Haixuan Wang, Hongbo Zheng, Jun Liu, Chengzhi Zhou, Wenlong Shao, Yuan Qiu, Jiancong Sun, Zhanhong Xie, Zhu Liang, Chenglin Yang, Xiuyu Cai, Chunxia Su, Wei Wang, Jianxing He, Wenhua Liang
Immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1) protein significantly improve survival in patients with advanced non-small-cell lung cancer (NSCLC), but its impact on early-stage ground-glass opacity (GGO) lesions remains unclear. This is a single-arm, phase II trial (NCT04026841) using Simon's optimal two-stage design, of which 4 doses of sintilimab (200 mg per 3 weeks) were administrated in 36 enrolled multiple primary lung cancer (MPLC) patients with persistent high-risk (Lung-RADS category 4 or had progressed within 6 months) GGOs...
April 19, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38627387/mettl14-downregulation-drives-s100a4-monocyte-derived-macrophages-via-myd88-nf-%C3%AE%C2%BAb-pathway-to-promote-mafld-progression
#28
JOURNAL ARTICLE
Yue-Fan Wang, Wen-Li Zhang, Zhi-Xuan Li, Yue Liu, Jian Tan, Hao-Zan Yin, Zhi-Chao Zhang, Xian-Jie Piao, Min-Hao Ruan, Zhi-Hui Dai, Si-Jie Wang, Chen-Yang Mu, Ji-Hang Yuan, Shu-Han Sun, Hui Liu, Fu Yang
Without intervention, a considerable proportion of patients with metabolism-associated fatty liver disease (MAFLD) will progress from simple steatosis to metabolism-associated steatohepatitis (MASH), liver fibrosis, and even hepatocellular carcinoma. However, the molecular mechanisms that control progressive MAFLD have yet to be fully determined. Here, we unraveled that the expression of the N6-methyladenosine (m6A) methyltransferase METTL14 is remarkably downregulated in the livers of both patients and several murine models of MAFLD, whereas hepatocyte-specific depletion of this methyltransferase aggravated lipid accumulation, liver injury, and fibrosis...
April 17, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38627366/phase-ii-study-of-novel-orally-pi3k%C3%AE-%C3%AE-inhibitor-tq-b3525-in-relapsed-and-or-refractory-follicular-lymphoma
#29
JOURNAL ARTICLE
Huaqing Wang, Jifeng Feng, Yanyan Liu, Zhengzi Qian, Da Gao, Xuehong Ran, Hui Zhou, Lihong Liu, Binghua Wang, Meiyun Fang, Hebing Zhou, Zhenqian Huang, Shi Tao, Zhuowen Chen, Liping Su, Hang Su, Yu Yang, Xiaobao Xie, Huijing Wu, Ping Sun, Guoyu Hu, Aibin Liang, Zhiming Li
This registration study assessed clinical outcomes of TQ-B3525, the dual phosphatidylinositol-3-kinase (PI3K) α/δ inhibitor, in relapsed and/or refractory follicular lymphoma (R/R FL). This phase II study (ClinicalTrials.gov NCT04324879. Registered March 27, 2020) comprised run-in stage and stage 2. R/R FL patients after ≥2 lines therapies received oral 20 mg TQ-B3525 once daily in a 28-day cycle until intolerable toxicity or disease progression. Primary endpoint was independent review committee (IRC)-assessed objective response rate (ORR)...
April 17, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38627360/pandemic-punch-sars-cov-2-hits-pancreas
#30
JOURNAL ARTICLE
Ninel Azoitei, Sandra Heller, Alexander Kleger
No abstract text is available yet for this article.
April 16, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38616203/poly-a-specific-rnase-parn-generates-and-regulates-mir-125a-5p-3-isoforms-displaying-an-altered-expression-in-breast-cancer
#31
LETTER
Luisa Tomasello, Shoshanah M Holub, Giovanni Nigita, Rosario Distefano, Carlo M Croce
No abstract text is available yet for this article.
April 15, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38616190/anti-lymphangiogenesis-for-boosting-drug-accumulation-in-tumors
#32
JOURNAL ARTICLE
Chunling Wang, Junchao Xu, Xiaoyu Cheng, Ge Sun, Fenfen Li, Guangjun Nie, Yinlong Zhang
The inadequate tumor accumulation of anti-cancer agents is a major shortcoming of current therapeutic drugs and remains an even more significant concern in the clinical prospects for nanomedicines. Various strategies aiming at regulating the intratumoral permeability of therapeutic drugs have been explored in preclinical studies, with a primary focus on vascular regulation and stromal reduction. However, these methods may trigger or facilitate tumor metastasis as a tradeoff. Therefore, there is an urgent need for innovative strategies that boost intratumoral drug accumulation without compromising treatment outcomes...
April 15, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38609366/infection-with-sars-cov-2-can-cause-pancreatic-impairment
#33
JOURNAL ARTICLE
Wei Deng, Linlin Bao, Zhiqi Song, Ling Zhang, Pin Yu, Yanfeng Xu, Jue Wang, Wenjie Zhao, Xiuqin Zhang, Yunlin Han, Yanhong Li, Jiangning Liu, Qi Lv, Xujian Liang, Fengdi Li, Feifei Qi, Ran Deng, Siyuan Wang, Yibai Xiong, Ruiping Xiao, Hongyang Wang, Chuan Qin
Evidence suggests associations between COVID-19 patients or vaccines and glycometabolic dysfunction and an even higher risk of the occurrence of diabetes. Herein, we retrospectively analyzed pancreatic lesions in autopsy tissues from 67 SARS-CoV-2 infected non-human primates (NHPs) models and 121 vaccinated and infected NHPs from 2020 to 2023 and COVID-19 patients. Multi-label immunofluorescence revealed direct infection of both exocrine and endocrine pancreatic cells by the virus in NHPs and humans. Minor and limited phenotypic and histopathological changes were observed in adult models...
April 12, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38594257/g-protein-coupled-receptors-gpcrs-advances-in-structures-mechanisms-and-drug-discovery
#34
REVIEW
Mingyang Zhang, Ting Chen, Xun Lu, Xiaobing Lan, Ziqiang Chen, Shaoyong Lu
G protein-coupled receptors (GPCRs), the largest family of human membrane proteins and an important class of drug targets, play a role in maintaining numerous physiological processes. Agonist or antagonist, orthosteric effects or allosteric effects, and biased signaling or balanced signaling, characterize the complexity of GPCR dynamic features. In this study, we first review the structural advancements, activation mechanisms, and functional diversity of GPCRs. We then focus on GPCR drug discovery by revealing the detailed drug-target interactions and the underlying mechanisms of orthosteric drugs approved by the US Food and Drug Administration in the past five years...
April 10, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38584163/thiamine-modified-metabolic-reprogramming-of-human-pluripotent-stem-cell-derived-cardiomyocyte-under-space-microgravity
#35
JOURNAL ARTICLE
Xinglong Han, Lina Qu, Miao Yu, Lingqun Ye, Liujia Shi, Guangfu Ye, Jingsi Yang, Yaning Wang, Hao Fan, Yong Wang, Yingjun Tan, Chunyan Wang, Qi Li, Wei Lei, Jianghai Chen, Zhaoxia Liu, Zhenya Shen, Yinghui Li, Shijun Hu
During spaceflight, the cardiovascular system undergoes remarkable adaptation to microgravity and faces the risk of cardiac remodeling. Therefore, the effects and mechanisms of microgravity on cardiac morphology, physiology, metabolism, and cellular biology need to be further investigated. Since China started constructing the China Space Station (CSS) in 2021, we have taken advantage of the Shenzhou-13 capsule to send human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) to the Tianhe core module of the CSS...
April 8, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38584157/the-gasdermin-family-emerging-therapeutic-targets-in-diseases
#36
REVIEW
Chenglong Zhu, Sheng Xu, Ruoyu Jiang, Yizhi Yu, Jinjun Bian, Zui Zou
The gasdermin (GSDM) family has garnered significant attention for its pivotal role in immunity and disease as a key player in pyroptosis. This recently characterized class of pore-forming effector proteins is pivotal in orchestrating processes such as membrane permeabilization, pyroptosis, and the follow-up inflammatory response, which are crucial self-defense mechanisms against irritants and infections. GSDMs have been implicated in a range of diseases including, but not limited to, sepsis, viral infections, and cancer, either through involvement in pyroptosis or independently of this process...
April 8, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38575611/protein-neddylation-and-its-role-in-health-and-diseases
#37
REVIEW
Shizhen Zhang, Qing Yu, Zhijian Li, Yongchao Zhao, Yi Sun
NEDD8 (Neural precursor cell expressed developmentally downregulated protein 8) is an ubiquitin-like protein that is covalently attached to a lysine residue of a protein substrate through a process known as neddylation, catalyzed by the enzyme cascade, namely NEDD8 activating enzyme (E1), NEDD8 conjugating enzyme (E2), and NEDD8 ligase (E3). The substrates of neddylation are categorized into cullins and non-cullin proteins. Neddylation of cullins activates CRLs (cullin RING ligases), the largest family of E3 ligases, whereas neddylation of non-cullin substrates alters their stability and activity, as well as subcellular localization...
April 5, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38575583/circulating-tumor-cells-shielded-with-extracellular-vesicle-derived-cd45-evade-t-cell-attack-to-enable-metastasis
#38
JOURNAL ARTICLE
Chuan Yang, Xueping Wang, Kenneth K W To, Caimei Cui, Min Luo, Shaocong Wu, Lamei Huang, Kai Fu, Can Pan, Zeyu Liu, Teng Fan, Caibo Yang, Fang Wang, Liwu Fu
Circulating tumor cells (CTCs) are precursors of distant metastasis in a subset of cancer patients. A better understanding of CTCs heterogeneity and how these CTCs survive during hematogenous dissemination could lay the foundation for therapeutic prevention of cancer metastasis. It remains elusive how CTCs evade immune surveillance and elimination by immune cells. In this study, we unequivocally identified a subpopulation of CTCs shielded with extracellular vesicle (EVs)-derived CD45 (termed as CD45+ CTCs) that resisted T cell attack...
April 5, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38570490/progression-from-ductal-carcinoma-in-situ-to-invasive-breast-cancer-molecular-features-and-clinical-significance
#39
REVIEW
Jing Wang, Baizhou Li, Meng Luo, Jia Huang, Kun Zhang, Shu Zheng, Suzhan Zhang, Jiaojiao Zhou
Ductal carcinoma in situ (DCIS) represents pre-invasive breast carcinoma. In untreated cases, 25-60% DCIS progress to invasive ductal carcinoma (IDC). The challenge lies in distinguishing between non-progressive and progressive DCIS, often resulting in over- or under-treatment in many cases. With increasing screen-detected DCIS in these years, the nature of DCIS has aroused worldwide attention. A deeper understanding of the biological nature of DCIS and the molecular journey of the DCIS-IDC transition is crucial for more effective clinical management...
April 3, 2024: Signal Transduction and Targeted Therapy
https://read.qxmd.com/read/38565886/xelox-capecitabine-plus-oxaliplatin-plus-bevacizumab-anti-vegf-a-antibody-with-or-without-adoptive-cell-immunotherapy-in-the-treatment-of-patients-with-previously-untreated-metastatic-colorectal-cancer-a-multicenter-open-label-randomized-controlled-phase-3
#40
RANDOMIZED CONTROLLED TRIAL
Qiu-Zhong Pan, Jing-Jing Zhao, Liang Liu, Dong-Sheng Zhang, Li-Ping Wang, Wen-Wei Hu, De-Sheng Weng, Xiang Xu, Yi-Zhuo Li, Yan Tang, Wei-Hong Zhang, Jie-Yao Li, Xiao Zheng, Qi-Jing Wang, Yong-Qiang Li, Tong Xiang, Li Zhou, Shuang-Ning Yang, Chen Wu, Rong-Xing Huang, Jia He, Wei-Jiao Du, Lu-Jun Chen, Yue-Na Wu, Bin Xu, Qiong Shen, Yi Zhang, Jing-Ting Jiang, Xiu-Bao Ren, Jian-Chuan Xia
Fluoropyrimidine-based combination chemotherapy plus targeted therapy is the standard initial treatment for unresectable metastatic colorectal cancer (mCRC), but the prognosis remains poor. This phase 3 trial (ClinicalTrials.gov: NCT03950154) assessed the efficacy and adverse events (AEs) of the combination of PD-1 blockade-activated DC-CIK (PD1-T) cells with XELOX plus bevacizumab as a first-line therapy in patients with mCRC. A total of 202 participants were enrolled and randomly assigned in a 1:1 ratio to receive either first-line XELOX plus bevacizumab (the control group, n = 102) or the same regimen plus autologous PD1-T cell immunotherapy (the immunotherapy group, n = 100) every 21 days for up to 6 cycles, followed by maintenance treatment with capecitabine and bevacizumab...
April 3, 2024: Signal Transduction and Targeted Therapy
journal
journal
52906
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.